BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takeshita T, Yan L, Asaoka M, Rashid O, Takabe K. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor. Sci Rep 2019;9:16942. [PMID: 31729458 DOI: 10.1038/s41598-019-53482-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Basseville A, Cordier C, Ben Azzouz F, Gouraud W, Lasla H, Panloup F, Campone M, Jézéquel P. Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy. Cancer Research Communications 2022;2:857-869. [DOI: 10.1158/2767-9764.crc-21-0090] [Reference Citation Analysis]
2 Wu R, Roy AM, Tokumaru Y, Gandhi S, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K. NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. Cancers (Basel) 2022;14:2962. [PMID: 35740627 DOI: 10.3390/cancers14122962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, Hatanaka Y, Hatanaka KC, Yan L, Takabe K. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol 2022;12:865024. [PMID: 35677163 DOI: 10.3389/fonc.2022.865024] [Reference Citation Analysis]
4 Chen T, Kim KY, Oh Y, Jeung HC, Chung KY, Roh MR, Zhang X. Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis. Cancers (Basel) 2022;14:2038. [PMID: 35454945 DOI: 10.3390/cancers14082038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Alshareeda AT, Nur Khatijah M, Al-sowayan BS. Nanotechnology: A revolutionary approach to prevent breast cancer recurrence. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2022.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Edinoff AN, Derise OC, Sheppard AJ, Miriyala S, Virgen CG, Kaye AJ, Niakan M, Cornett EM, Kaye AD. The Influence of Analgesic Modalities on Postoperative Cancer Recurrence. Anesth Pain Med 2022;12. [DOI: 10.5812/aapm.123463] [Reference Citation Analysis]
7 Mitola G, Falvo P, Bertolini F. New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies. Life (Basel) 2021;11:1131. [PMID: 34833007 DOI: 10.3390/life11111131] [Reference Citation Analysis]
8 Lee KT, Kim S, Jeon BJ, Pyon JK, Mun GH, Ryu JM, Lee SK, Yu J, Kim SW, Lee JE, Nam SJ, Bang SI. Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. JAMA Surg 2020;155:1132-40. [PMID: 33026424 DOI: 10.1001/jamasurg.2020.4124] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
9 Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol 2021;4:747. [PMID: 34135460 DOI: 10.1038/s42003-021-02257-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
10 Okano M, Oshi M, Mukhopadhyay S, Qi Q, Yan L, Endo I, Ohtake T, Takabe K. Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival. Cancers (Basel) 2021;13:2933. [PMID: 34208219 DOI: 10.3390/cancers13122933] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tokumaru Y, Oshi M, Patel A, Tian W, Yan L, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Organoids Are Limited in Modeling the Colon Adenoma-Carcinoma Sequence. Cells 2021;10:488. [PMID: 33668713 DOI: 10.3390/cells10030488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mohamud JA, Gu J, Halane SA, Mohamud FA. Role of MRI in Differentiation between Postoperative Tumoral Recurrence and Radiation-Induced Brain Necrosis in Patients of Glioblastoma Multiform. OJRad 2021;11:45-53. [DOI: 10.4236/ojrad.2021.112005] [Reference Citation Analysis]
13 Takeshita T, Torigoe T, Yan L, Huang JL, Yamashita H, Takabe K. The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. Cancers (Basel) 2020;13:E110. [PMID: 33396390 DOI: 10.3390/cancers13010110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
14 Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer. Cancers (Basel) 2020;12:E3856. [PMID: 33371179 DOI: 10.3390/cancers12123856] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
15 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients. J Immunol Res 2020;2020:5618786. [PMID: 33457427 DOI: 10.1155/2020/5618786] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
16 Schulze A, Oshi M, Endo I, Takabe K. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer. Int J Mol Sci 2020;21:E8127. [PMID: 33143224 DOI: 10.3390/ijms21218127] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
17 Tokumaru Y, Le L, Asaoka M, Futamura M, Ishikawa T, Yoshida K, Takabe K. Should we target "intermediate expression" of HER2 in older estrogen receptor positive patients? Transl Cancer Res 2020;9:4056-9. [PMID: 33102162 DOI: 10.21037/tcr-20-2231] [Reference Citation Analysis]
18 Oshi M, Asaoka M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Zsiros E, Ishikawa T, Endo I, Takabe K. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancers (Basel) 2020;12:E3038. [PMID: 33086518 DOI: 10.3390/cancers12103038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
19 Oshi M, Tokumaru Y, Asaoka M, Yan L, Satyananda V, Matsuyama R, Matsuhashi N, Futamura M, Ishikawa T, Yoshida K, Endo I, Takabe K. M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci Rep 2020;10:16554. [PMID: 33024179 DOI: 10.1038/s41598-020-73624-w] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 25.0] [Reference Citation Analysis]
20 Oshi M, Newman S, Tokumaru Y, Yan L, Matsuyama R, Endo I, Katz MHG, Takabe K. High G2M Pathway Score Pancreatic Cancer is Associated with Worse Survival, Particularly after Margin-Positive (R1 or R2) Resection. Cancers (Basel) 2020;12:E2871. [PMID: 33036243 DOI: 10.3390/cancers12102871] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
21 Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I, Takabe K. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci 2020;21:E6968. [PMID: 32971948 DOI: 10.3390/ijms21186968] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 25.5] [Reference Citation Analysis]
22 Chouliaras K, Tokumaru Y, Asaoka M, Oshi M, Attwood KM, Yoshida K, Ishikawa T, Takabe K. Prevalence and clinical relevance of tumor-associated tissue eosinophilia (TATE) in breast cancer. Surgery 2021;169:1234-9. [PMID: 32958266 DOI: 10.1016/j.surg.2020.07.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Gondhowiardjo SA, Handoko, Jayalie VF, Apriantoni R, Barata AR, Senoaji F, Utami IJW, Maubere F, Nuryadi E, Giselvania A. Tackling Resistance to Cancer Immunotherapy: What Do We Know? Molecules 2020;25:E4096. [PMID: 32911646 DOI: 10.3390/molecules25184096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
24 Tokumaru Y, Oshi M, Katsuta E, Yan L, Huang JL, Nagahashi M, Matsuhashi N, Futamura M, Yoshida K, Takabe K. Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation. Int J Mol Sci 2020;21:E5744. [PMID: 32796516 DOI: 10.3390/ijms21165744] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
25 Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M, Matsuyama R, Endo I, Takabe K. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer. Cells 2020;9:E1643. [PMID: 32650578 DOI: 10.3390/cells9071643] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
26 Gandhi S, Elkhanany A, Oshi M, Dai T, Opyrchal M, Mohammadpour H, Repasky EA, Takabe K. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer. Int J Mol Sci 2020;21:E4635. [PMID: 32629782 DOI: 10.3390/ijms21134635] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
27 Oshi M, Katsuta E, Yan L, Ebos JML, Rashid OM, Matsuyama R, Endo I, Takabe K. A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer. Cancers (Basel) 2020;12:E1148. [PMID: 32370309 DOI: 10.3390/cancers12051148] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
28 Tokumaru Y, Katsuta E, Oshi M, Sporn JC, Yan L, Le L, Matsuhashi N, Futamura M, Akao Y, Yoshida K, Takabe K. High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer. Int J Mol Sci 2020;21:E3045. [PMID: 32357442 DOI: 10.3390/ijms21093045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
29 Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R, Endo I, Takabe K. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci 2020;21:E2921. [PMID: 32331421 DOI: 10.3390/ijms21082921] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 26.5] [Reference Citation Analysis]
30 Yuan Y, Zhou Y, Li Y, Hill C, Ewing RM, Jones MG, Davies DE, Jiang Z, Wang Y. Deconvolution of RNA-Seq Analysis of Hyperbaric Oxygen-Treated Mice Lungs Reveals Mesenchymal Cell Subtype Changes. Int J Mol Sci 2020;21:E1371. [PMID: 32085618 DOI: 10.3390/ijms21041371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]